I beg to move,
That leave be given to bring in a Bill to make provision about the liability of practitioners, and of the organisation which employs the practitioner, where a practitioner prescribes an unlicensed medicine to or carries out a non-standard treatment on a person who is terminally ill; to make provision about the import, storage and use of equipment and unlicensed medicines for the purpose of such prescriptions or such treatment; and for connected purposes.
Advances in medical science wait for no man or woman—unless, of course, they are one of the thousands of people in the UK each year diagnosed with a rare cancer. In that case, they are likely to receive NHS treatment that has remained unchanged for more than 30 years, with no improvement in outcomes, no access to drug trials and no access to the huge progress that has been made in individualised cancer vaccines or immunotherapy.
It does not have to be that way. In Germany, medical practitioners can offer experimental treatments to patients with a terminal diagnosis without fear that they, or the organisations that employ them, will be held liable or penalised. They can offer patients a lifeline that doctors in the UK are not allowed to offer. I am introducing this Bill to protect clinicians in the same way and to allow patients access to the latest medical treatments.
In truth, we know this ten-minute rule Bill has no prospect of becoming law. However, it serves another purpose: to give a voice to the thousands of terminally ill patients and the ordeal they are forced to endure in search of a lifeline; to expose the culture of fear among medical professionals in the NHS surrounding individualised treatment; and to suggest a better way forward.
Excuse my German pronunciation, but Individuelle Heilversuche is the German law that allows doctors to provide personalised, individual treatment plans. When a terminally ill patient has run out of traditional treatment options, medical practitioners can use treatments that have not been fully approved, or that have been approved for other purposes, as part of individual treatment programmes. They are able to prescribe drugs for off-label use—drugs that are known to save lives but are not yet available to patients with a specific condition. How can it be right not to offer the same rights to patients in the UK? Instead, the NHS—and healthcare in general—abandons them to die when the outdated and inadequate standard care fails. Understandably, many fight and take the hard choice to travel internationally—in this case, to Germany—to find the treatments denied to them in their own country.
I know this path, as I walked it with my sister. I held her head as she was sick into a bin on the concourse at Heathrow airport’s terminal 5. I obscured her from flight attendants in fear that they would take her off the plane, and that we would not get to Düsseldorf. One night, I wondered how I would explain her death in a foreign city, in a country where I did not speak the language or understand the emergency care. But I would do it all again, because I wanted to extend her life and there was nothing for her here in the UK.